Patient characteristics and cycle characteristics
In total, 364 women were enrolled. Table 1 shows the comparison of basic patient characteristics and the cycle characteristics between ovarian stimulation groups stratified by age. No statistically significant differences were found between the groups with respect to age, duration of infertility, proportion of secondary infertility, body mass index (BMI), AMH, AFC, baseline hormones, Gn duration and total dosage of Gn (P > 0.05).
Table 1
Patient characteristics and controlled ovarian stimulation characteristics between groups stratified by age.
|
≤35 years
|
|
>35 years
|
|
|
PPOS with CC group
(HMG/MPA/CC; n = 73)
|
Standard PPOS group
(HMG/MPA; n = 59)
|
P-value
|
PPOS with CC group
(HMG/MPA/CC; n = 150)
|
Standard PPOS group
(HMG/MPA; n = 82)
|
P-value
|
Age (years)
|
30.82±2.66
|
30.71±3.19
|
0.825
|
40.25±3.02
|
39.90±3.31
|
0.423
|
Duration of infertility (years)
|
3.29±2.46
|
3.96±2.80
|
0.148
|
3.62±3.28
|
4.36±4.07
|
0.138
|
Secondary infertility, % (n)
|
64.4 (47/73)
|
69.5 (41/59)
|
0.536
|
65.3 (98/150)
|
62.2 (51/82)
|
0.634
|
Cause of infertility, % (n)
|
|
|
NDa
|
|
|
NDa
|
Tubal factor
|
67.1 (49/73)
|
50.8 (30/59)
|
|
61.33 (92/150)
|
62.2 (51/82)
|
|
Male factor
|
56.16 (41/73)
|
37.3 (22/59)
|
|
52 (78/150)
|
47.6 (39/82)
|
|
Other factors
|
17.8 (13/73)
|
8.5 (5/59)
|
|
16.7 (25/150)
|
15.9 (13/82)
|
|
Unknown factor
|
13.7 (10/73)
|
11.9 (7/59)
|
|
6.7 (10/150)
|
11.0 (9/82)
|
|
Failed cycles
|
1.81±1.45
|
2.11±1.37
|
0.226
|
1.77±1.52
|
2.07±1.65
|
0.164
|
BMI (kg/M2)
|
22.47±3.58
|
21.39±3.14
|
0.067
|
22.56±2.69
|
22.17±2.75
|
0.295
|
AMH (ng/ml)
|
0.88±0.61
|
0.95±0.64
|
0.530
|
0.88±0.58
|
0.86±0.49
|
0.785
|
Antral follicle counts
|
6.22±2.08
|
6.15±2.03
|
0.854
|
5.69±2.25
|
6.01±2.31
|
0.298
|
Baseline hormones
|
FSH (IU/L)
|
11.13±5.33
|
11.23±4.18
|
0.904
|
11.10±5.02
|
12.19±4.96
|
0.116
|
LH (IU/L)
|
4.49±2.45
|
4.13±2.05
|
0.370
|
4.22±2.22
|
4.68±2.29
|
0.131
|
E2 (pg/ml)
|
53.44±34.97
|
53.29±29.55
|
0.980
|
58.57±44.35
|
59.78±45.34
|
0.843
|
P (ng/ml)
|
0.55±0.31
|
0.60±0.41
|
0.380
|
0.52±0.46
|
0.51±0.40
|
0.848
|
Gn duration (days)
|
9.32±2.45
|
9.90±3.75
|
0.284
|
9.71±2.28
|
10.05±3.06
|
0.386
|
Total dosage of Gn (IU)
|
1975.34±555.86
|
2052.54±1448.86
|
0.700
|
2050.53±575.89
|
1993.29±971.05
|
0.626
|
Percentage of women with profound pituitary suppression, % (n)
|
0.0 (0/73)
|
18.6 (11/59)
|
<0.001
|
1.3 (2/150)
|
11.0 (9/82)
|
0.002
|
Incidence of LH level ≥10 IU/L on the trigger day, % (n)
|
9.6 (7/73)
|
3.4 (2/59)
|
0.187
|
12.7 (22/150)
|
4.9 (4/82)
|
0.028
|
CC, clomiphene citrate; PPOS, progestin-primed ovarian stimulation; MPA, medroxyprogesterone acetate; BMI, body mass index; AMH, anti-Müllerian hormone; AFC, antral follicle count; FSH, follicle-stimulating hormone; LH, luteinizing hormone; E2, estradiol; P, progesterone; Gn, gonadotropin; ND, not defined.
a Because someone may have more than 1 cause of infertility.
|
Controlled ovarian stimulation and embryological outcomes
The COS and embryological outcomes of both groups are presented in Table 2. There was no statistical difference found in 2PN rate and number of 2PN cleavage between the groups. No difference was observed in the cancellation rate prior to oocyte retrieval (P >0.05). For women aged above 35 years, the mean number of oocytes retrieved in PPOS with CC group was significantly higher than those in standard PPOS group (4.23 vs. 3.50, P =0.034). However, the oocyte maturation rate in PPOS with CC group was significantly lower than those in standard PPOS group (84.7% vs. 89.9%, P =0.034). Compared with women aged below 35 years in standard PPOS group, a significantly higher number of high-quality cleavage-stage embryos and a significantly lower no high-quality cleavage-stage embryos cycles rate were noted in PPOS with CC group (1.96 vs. 1.38, P =0.018 and 11.0% vs 33.9%, P =0.001, respectively), while no difference was found in the other subgroups.
Table 2
Clinical outcomes between groups stratified by age.
|
≤ 35 years
|
|
> 35 years
|
|
|
PPOS with CC group
(HMG/MPA/CC; n = 73)
|
Standard PPOS group
(HMG/MPA; n = 59)
|
P-value
|
PPOS with CC group
(HMG/MPA/CC; n = 150)
|
Standard PPOS group
(HMG/MPA; n = 82)
|
P-value
|
No. of > 14mm follicles on trigger day
|
4.34 ± 2.29
|
3.20 ± 1.57
|
0.001
|
3.51 ± 1.89
|
3.28 ± 1.93
|
0.374
|
No. of oocytes retrieved
|
5.10 ± 2.72
|
4.44 ± 3.97
|
0.264
|
4.23 ± 2.64
|
3.50 ± 2.16
|
0.034
|
ICSI MII oocytes rate, % (n)
|
87.3 (165/189)
|
80.0 (56/70)
|
0.140
|
82.5 (274/332)
|
88.3 (121/137)
|
0.118
|
Oocyte maturation rate, % (n)
|
85.2 (317/372)
|
82.8 (217/262)
|
0.416
|
84.7 (537/634)
|
89.9 (258/287)
|
0.034
|
2PN rate of IVF oocytes, % (n)
|
78.9 (120/152)
|
72.0 (116/161)
|
0.157
|
70.7 (186/263)
|
79.6 (109/137)
|
0.057
|
2PN rate of ICSI oocytes, % (n)
|
79.4 (131/165)
|
82.1 (46/56)
|
0.656
|
80.7 (221/274)
|
79.3 (96/121)
|
0.762
|
No. of 2PN cleavage
|
3.54 ± 2.17
|
2.89 ± 2.00
|
0.089
|
2.75 ± 1.82
|
2.55 ± 1.57
|
0.407
|
No. of high-quality cleavage-stage embryos
|
1.96 ± 1.44
|
1.38 ± 1.26
|
0.018
|
1.47 ± 1.28
|
1.46 ± 1.28
|
0.983
|
No high-quality cleavage-stage embryos cycles rate, % (n)
|
11.0 (8/73)
|
33.9 (20/59)
|
0.001
|
(38/150)
|
(19/82)
|
0.715
|
Cancellation rate prior to oocyte retrieval, % (n)
|
2.7 (2/73)
|
0.0 (0/59)
|
0.502
|
0.0 (0/150)
|
2.4 (2/82)
|
0.124
|
FET cycles
|
56
|
35
|
|
92
|
57
|
|
No. of transferred embryos
|
1.86 ± 0.35
|
1.74 ± 0.44
|
0.202
|
1.79 ± 0.41
|
1.79 ± 0.41
|
0.954
|
Endometrial thickness (mm)
|
9.86 ± 1.87
|
9.37 ± 1.89
|
0.233
|
9.69 ± 1.86
|
9.21 ± 1.69
|
0.119
|
Clinical pregnancy rate, % (n)
|
44.6 (25/56)
|
54.3 (19/35)
|
0.371
|
35.9 (33/92)
|
28.1 (16/57)
|
0.325
|
Ongoing pregnant rate, % (n)
|
39.3 (22/56)
|
51.4 (18/35)
|
0.256
|
22.8 (21/92)
|
17.5 (10/57)
|
0.440
|
Implantation rate, % (n)
|
29.8 (31/104)
|
41.0 (25/61)
|
0.143
|
21.8 (36/165)
|
17.6 (18/102)
|
0.410
|
Miscarriage rate, % (n)
|
12.0 (3/25)
|
5.3 (1/19)
|
0.622
|
36.4 (12/33)
|
25.0 (4/16)
|
0.526
|
Ectopic pregnancy rate, % (n)
|
0
|
0
|
NDa
|
3.0 (1/33)
|
6.3 (1/16)
|
1.000
|
Live birth, % (n)
|
39.3 (22/56)
|
51.4 (18/35)
|
0.256
|
21.7 (20/92)
|
17.5 (10/57)
|
0.535
|
CC, clomiphene citrate; PPOS, progestin-primed ovarian stimulation; MPA, medroxyprogesterone acetate; No., number; ICSI, Intracytoplasmic sperm injection; FET, frozen-thawed embryo transfer; ND, not defined. |
a Because someone may have more than 1 cause of infertility. |
Hormone profile during treatment
The serum concentrations of FSH, LH, E2 and P in the two groups stratified by age are presented in Figure 1. In both groups, the FSH levels increased after Gn administration, and no difference was found between the groups (P >0.05). The serum E2 levels and P levels increased gradually in both groups after Gn administration. The serum E2 levels and P levels on day of trigger in the PPOS with CC group were significantly higher than those in all subgroups of the standard PPOS group (1974.68±1239.05 pg/ml vs. 1143.19±742.72 pg/ml, P <0.001, 1777.37±1148.10 pg/ml vs. 1220.22±796.84 pg/ml, P <0.001, 1.02±0.50 ng/ml vs. 0.83±0.53 ng/ml, P =0.043, 0.99±0.87 ng/ml vs. 0.69±0.40 ng/ml, P <0.001, respectively).
The LH levels of the two groups showed different trends. The LH levels in the PPOS with CC group increased first and then remained steady at a range of 5.52–6.61 IU/L; in contrast, the LH levels in the standard PPOS group remained at a certain level initially and then slightly decreased. There was no significant difference in the value of basal LH between the groups (P >0.05), whereas the LH levels on day 7–10 and day of trigger in the PPOS with CC group were significantly higher than that in all subgroups of the standard PPOS group (P <0.05).
As shown in Table 1, the percentage of women with profound pituitary suppression was significantly lower in the PPOS with CC group than that in standard PPOS group (0.0% vs 18.6%, P <0.001 and 1.3% vs 11.0%, P =0.002). In addition, compared with the standard PPOS group, the percentage of patients with LH levels above 10 IU/L on the trigger day was higher in the PPOS with CC group, especially for patients aged above 35 years (12.7% vs. 4.9%, P =0.028). All patients with LH levels above 10 IU/L on the trigger day confirmed the sonolucent follicles are still there by transvaginal ultrasound just before the planned oocyte retrieval and underwent oocyte retrieval, among which only two patients had no oocytes retrieved and only one patient had no mature oocytes being retrieved.
Pregnancy outcomes
In this study, 29 women did not complete the FET cycles for no viable embryos and 62 women for personal reasons before the end of the study. In total, 273 women completed FET cycles during the 18 months of follow-up, among which 4 women transferred with embryos collected from twice oocyte retrieval and 29 women transferred with no high-quality cleavage-stage embryos or good morphology blastocysts. The discontinuation rate of the cycle, which achieved at least one high-quality cleavage-stage embryos, was comparable between the groups (10.3% [4/39] vs 13.8% [9/65]; 9.5% [6/63] vs 17.9% [20/112]; P >0.05). Only 240 women were transferred with at least one high-quality cleavage-stage embryos or good morphology blastocysts, which were included in the analysis of pregnancy outcomes (Table 2). The rate of blastocysts transfers was similar between the groups in all subgroups (5.4% [3/56] vs 14.3% [5/35]; 6.5% [6/92] vs 0% [0/57]; P >0.05). The clinical pregnancy rate, ongoing pregnant rate, implantation rate, miscarriage rate, ectopic pregnancy rate and live birth rate were comparable between the groups in all subgroups (P >0.05).
All newborns were examined with no congenital malformation except that oesophageal atresia was found in one baby of the PPOS with CC group and cleft lip and palate in one baby of the standard PPOS group.
Furthermore, we assess the clinical outcomes of patients with LH levels above 1 IU/L, but below 10 IU/L on the trigger day (Table 3). We found similar trend of the outcomes in these patients as in the whole population.
Table 3
Clinical outcomes patients with LH levels above 1 IU/L, but below 10 IU/L on the trigger day between groups stratified by age.
|
≤ 35 years
|
|
> 35 years
|
|
|
PPOS with CC group
(HMG/MPA/CC; n = 66)
|
Standard PPOS group
(HMG/MPA; n = 46)
|
P-value
|
PPOS with CC group
(HMG/MPA/CC; n = 126 )
|
Standard PPOS group
(HMG/MPA; n = 69)
|
P-value
|
No. of > 14mm follicles on trigger day
|
4.50 ± 2.82
|
3.15 ± 1.61
|
< 0.001
|
3.66 ± 1.85
|
3.51 ± 1.99
|
0.595
|
No. of oocytes retrieved
|
5.38 ± 2.59
|
4.65 ± 4.32
|
0.269
|
4.43 ± 2.67
|
3.72 ± 2.23
|
0.064
|
ICSI MII oocytes rate, % (n)
|
86.9 (159/183)
|
78.3 (47/60)
|
0.110
|
83.0 (230/277)
|
89.5 (102/114)
|
0.106
|
Oocyte maturation rate, % (n)
|
84.5 (300/355)
|
81.3 (174/214)
|
0.322
|
85.7 (478/558)
|
90.7 (233/257)
|
0.047
|
2PN rate of IVF oocytes, % (n)
|
78.0 (110/141)
|
70.1 (89/127)
|
0.138
|
70.2 (174/248)
|
79.4 (104/131)
|
0.053
|
2PN rate of ICSI oocytes, % (n)
|
79.2 (126/159)
|
80.9 (38/47)
|
0.810
|
83.0 (191/230)
|
79.4 (81/102)
|
0.428
|
No. of 2PN cleavage
|
3.58 ± 2.18
|
2.76 ± 2.10
|
0.051
|
2.90 ± 1.85
|
2.67 ± 1.59
|
0.383
|
No. of high-quality cleavage-stage embryos
|
2.02 ± 1.47
|
1.22 ± 1.25
|
0.003
|
1.55 ± 1.31
|
1.54 ± 1.31
|
0.954
|
No high-quality cleavage-stage embryos cycles rate, % (n)
|
9.1 (6/66)
|
37.0 (17/46)
|
< 0.001
|
21.4 (27/126)
|
18.8 (13/69)
|
0.669
|
Cancellation rate prior to oocyte retrieval, % (n)
|
3.0 (2/66)
|
0.0 (0/46)
|
0.512
|
0.0 (0/126)
|
2.9 (2/69)
|
0.124
|
FET cycles
|
52
|
25
|
|
79
|
51
|
|
No. of transferred embryos
|
1.87 ± 0.35
|
1.72 ± 0.46
|
0.168
|
1.81 ± 0.40
|
1.80 ± 0.40
|
0.931
|
Endometrial thickness (mm)
|
9.90 ± 1.91
|
9.32 ± 1.94
|
0.221
|
9.89 ± 1.87
|
9.34 ± 1.73
|
0.092
|
Clinical pregnancy rate, % (n)
|
44.2 (23/52)
|
56.0 (14/25)
|
0.333
|
36.7 (29/79)
|
29.4 (15/51)
|
0.391
|
Ongoing pregnant rate, % (n)
|
38.5 (20/52)
|
52.0 (13/25)
|
0.261
|
21.5 (17/79)
|
19.6 (10/51)
|
0.793
|
Implantation rate, % (n)
|
29.9 (29/97)
|
44.2 (19/43)
|
0.100
|
22.4 (32/143)
|
18.5 (17/92)
|
0.473
|
Miscarriage rate, % (n)
|
13.0 (3/23)
|
7.1 (1/14)
|
1.000
|
37.9 (11/29)
|
20.0 (3/15)
|
0.314
|
Ectopic pregnancy rate, % (n)
|
0
|
0
|
NDa
|
3.4 (1/29)
|
6.7 (1/15)
|
1.000
|
Live birth, % (n)
|
38.5 (20/52)
|
52.0 (13/25)
|
0.261
|
21.5 (17/79)
|
19.6 (10/51)
|
0.793
|
CC, clomiphene citrate; PPOS, progestin-primed ovarian stimulation; MPA, medroxyprogesterone acetate; No., number; ICSI, intracytoplasmic sperm injection; FET, frozen-thawed embryo transfer; ND, not defined. |
a Because someone may have more than 1 cause of infertility. |